|
Malignant neoplasm of breast
|
0.320 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Lung Neoplasms
|
0.020 |
AlteredExpression
|
group |
LHGDN |
Up-regulation of ALG-2 in hepatomas and lung cancer tissue.
|
12819013 |
2003 |
|
melanoma
|
0.010 |
AlteredExpression
|
disease |
LHGDN |
ALG-2 and its putative target molecule, Alix/AIP1, are localized primarily in the cytoplasm of melanocytes and melanoma cells independent of the intracellular Ca(2+) concentration or the activation of apoptosis.
|
15366927 |
2004 |
|
Malignant melanoma of eye
|
0.010 |
Biomarker
|
disease |
BEFREE |
Ca2+ binding to EF hands 1 and 3 is essential for the interaction of apoptosis-linked gene-2 with Alix/AIP1 in ocular melanoma.
|
15366927 |
2004 |
|
Adenocarcinoma of lung (disorder)
|
0.010 |
Biomarker
|
disease |
BEFREE |
Quantitative PCR also validated the amplification and overexpression of PDCD6 and TERT on chromosome 5p and the prognostic significance of PDCD6 in early stage ADC patients.
|
18632575 |
2008 |
|
Malignant neoplasm of stomach
|
0.010 |
Biomarker
|
disease |
BEFREE |
We identified PDCD6 as a prognostic biomarker in patients with unresected gastric cancer using endoscopic biopsy samples.
|
18957060 |
2008 |
|
Stomach Neoplasms
|
0.010 |
AlteredExpression
|
group |
LHGDN |
Identification of prognostic biomarkers in gastric cancer using endoscopic biopsy samples.
|
18957060 |
2008 |
|
Stomach Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
We identified PDCD6 as a prognostic biomarker in patients with unresected gastric cancer using endoscopic biopsy samples.
|
18957060 |
2008 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
No correlation was found between ALG-2 staining intensity and survival of patients with lung, breast or colon cancer. siRNA mediated ALG-2 downregulation led to a significant reduction in viability of HeLa cells indicating that ALG-2 may contribute to tumor development and expansion.
|
19383317 |
2008 |
|
Malignant tumor of colon
|
0.010 |
Biomarker
|
disease |
BEFREE |
No correlation was found between ALG-2 staining intensity and survival of patients with lung, breast or colon cancer. siRNA mediated ALG-2 downregulation led to a significant reduction in viability of HeLa cells indicating that ALG-2 may contribute to tumor development and expansion.
|
19383317 |
2008 |
|
Colon Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
No correlation was found between ALG-2 staining intensity and survival of patients with lung, breast or colon cancer. siRNA mediated ALG-2 downregulation led to a significant reduction in viability of HeLa cells indicating that ALG-2 may contribute to tumor development and expansion.
|
19383317 |
2008 |
|
Endogenous depression
|
0.300 |
Biomarker
|
disease |
PSYGENET |
Gene expression in patients with endogenous depression was similar to that in the normal controls, except for upregulation of five genes (APP, CREBBP, GNAS, PDCD2 and PDCD6).
|
19955554 |
2010 |
|
Malignant Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Both PDCD6 and cisplatin respectively inhibited cancer cell proliferation in a dose-dependent manner.
|
22142513 |
2012 |
|
Primary malignant neoplasm
|
0.070 |
Biomarker
|
group |
BEFREE |
Both PDCD6 and cisplatin respectively inhibited cancer cell proliferation in a dose-dependent manner.
|
22142513 |
2012 |
|
Carcinogenesis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
To define the roles of PDCD6 and cisplatin in tumorigenesis, we either over-expressed PDCD6 or treated it with cisplatin in SKOV-3 ovarian cancer cells.
|
22142513 |
2012 |
|
Malignant Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Programmed cell death 6 (PDCD6) beside its known proapoptotic functions may be a player in survival pathways in cancer.
|
22369209 |
2012 |
|
Primary malignant neoplasm
|
0.070 |
Biomarker
|
group |
BEFREE |
Programmed cell death 6 (PDCD6) beside its known proapoptotic functions may be a player in survival pathways in cancer.
|
22369209 |
2012 |
|
Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
Patients with medium or high levels of PDCD6 mRNA were at higher risk for disease progression, compared to those with low levels (HR, 1.29; P = 0.024 for medium levels; and HR, 1.57; P = 0.045 for high levels) after adjusting for age, disease stage, tumor grade, histologic type and residual tumor size.
|
22369209 |
2012 |
|
Epithelial ovarian cancer
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Significantly, the level of PDCD6 expression in epithelial ovarian cancer correlates with clinical progression.
|
22369209 |
2012 |
|
Tumor Cell Invasion
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
PDCD6 is highly expressed in metastatic ovarian cancer cells and positively regulates cell migration and invasion.
|
22369209 |
2012 |
|
Carcinoma, Ovarian Epithelial
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Significantly, the level of PDCD6 expression in epithelial ovarian cancer correlates with clinical progression.
|
22369209 |
2012 |
|
Endometriosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
In conclusion, the current study indicates that PDCD6 gene may be a new susceptibility gene to endometriosis.
|
23137875 |
2013 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
PDCD6, the encoding gene for programmed cell death protein 6, may function as a tumor suppressor gene.
|
23167403 |
2012 |
|
Malignant neoplasm of lung
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Genetic variation in PDCD6 and susceptibility to lung cancer.
|
23167403 |
2012 |
|
Carcinoma of lung
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Genetic variation in PDCD6 and susceptibility to lung cancer.
|
23167403 |
2012 |